Avedro Secures $43,000,000 Series D Funding

  • Feed Type
  • Date
    3/6/2013
  • Company Name
    Avedro
  • Mailing Address
    230 Third Avenue Waltham, MA 02451
  • Company Description
    Avedro’s Keraflex is not laser eye surgery – it is a non-incisional, non-invasive procedure currently under clinical study for the correction of myopia and the treatment of keratoconus. Unlike LASIK and other laser vision correction procedures, Keraflex offers peace of mind because it does not cut a flap in the cornea nor does it remove any corneal tissue. Evidence suggests this approach will preserve the all important bio-mechanical integrity of the cornea.
  • Website
    http://www.avedro.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $43,000,000
  • Transaction Round
    Series D
  • Proceeds Purposes
    Proceeds from this financing will allow us to execute on both our global commercialization strategy and our US FDA approval strategy.
  • M&A Terms
  • Venture Investor
    Abingworth Management
  • Venture Investor
    Third Point
  • Venture Investor
    Undisclosed

By posting a comment, you agree to our terms and conditions.